Fig. 4
From: Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
MHCC97H and JHH5 tumor growth inhibition by INC280 and MetMab in vivo. MHCC97H (a) or JHH5 cells (b) were implanted subcutaneously into SCID or SCIDhgf mice to induce tumor growth followed by treatment with INC280 (30Â mg/kg, daily oral gavage) for 3Â weeks or MetMAb (5 or 30Â mg/kg, i.p. one time dose). Combination refers to INC280 (30Â mg/kg) plus MetAb at 5Â mg/kg. Tumor growth was measured by a caliper twice a week